Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 55

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Chronic myelomonocytic leukaemia

Recruiting

Study of Azacitidine, Venetoclax, and Tagraxofusp for Patients with Higher-Risk Chronic Myelomonocytic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:TAGRAXOFUSP
  • Sponsor:Gcp-Service International West GmbH

Chronic myeloid leukaemia

Recruiting

Study of Olverembatinib and Bosutinib for Patients with Chronic Phase Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Ascentage Pharma Group Inc.

Plasmablastic lymphoma

Recruiting

Study on the Effects and Safety of Daratumumab, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Plasmablastic Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Fondazione Italiana Linfomi Ets

Breast cancer female

Recruiting

Study on Imaging and Treatment Prediction for Metastatic Breast Cancer Using Gallium (68Ga) Tezatabep Matraxetan and Trastuzumab Deruxtecan

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Gallium (68Ga) Tezatabep Matraxetan
  • Sponsor:Karolinska University Hospital

Uterine leiomyoma

Recruiting

Study on Reducing Bleeding Risk in Fibroid Surgery Using Misoprostol for Patients Undergoing Myomectomy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Misoprostol
  • Sponsor:University Hospital Of Clermont-Ferrand

Testicular seminoma (pure) stage I

Recruiting

Study Comparing Chemotherapy Options for Patients with Stage I Testicular Cancer: Bleomycin, Etoposide, Cisplatin vs. Carboplatin

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Bleomycin
  • Sponsor:St. Olavs Hospital HF

Pancreatic carcinoma metastatic+1

Recruiting

Study of TCR-Modified T Cell Therapy with ANOC-001, ANOC-002, and ANOC-003 for Adults with Advanced Pancreatic Cancer

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:ANOC-001
  • Sponsor:Anocca AB

Squamous cell carcinoma of head and neck

Recruiting

Study of Cetuximab and Paclitaxel for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Pembrolizumab Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Grupo Espanol De Tratamiento De Tumores De Cabeza Y Cuello

Pancreatic carcinoma

Recruiting

Study Comparing Gemcitabine and Paclitaxel with Drug Combination for Patients with Advanced Pancreatic Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Fondazione GONO G.I.

Hepatocellular carcinoma+1

Recruiting

Study of drug combinations including cisplatin, carboplatin, doxorubicin, fluorouracil, vincristine, etoposide, irinotecan, gemcitabine, oxaliplatin and sorafenib for children with hepatoblastoma or hepatocellular carcinoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:The University Of Birmingham

Asthma+1

Recruiting

Study of Tezepelumab effects on airway barrier function in patients with severe asthma, with or without chronic rhinosinusitis with nasal polyps

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:Medical University Of Vienna

Ovarian cancer recurrent

Recruiting

Study of Olaparib for Patients with Recurrent Ovarian Cancer Without BRCA Gene Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.